We found that DPP-4 inhibitors may reduce the risk for mortality, hospitalization, hypoglycaemia and adverse events leading to discontinuation and may have little impact on pancreatitis suggesting that DPP-4 inhibitors have a better benefit–risk ratio than sulfonylureas in older patients. Here, DPP4 is linked to pancreatitis.